HYDROXYCHLOROQUINE TO PREVENT SARS-COV-2 INFECTIO

Not Applicable

Suspended

• Conditions: -B972 Coronavirus as the cause of diseases classified to other chapters; Coronavirus as the cause of diseases classified to other chapters; B972

• Registration Number: PER-011-20
• Lead Sponsor: IVERSIDAD PERUANA CAYETANO HEREDIA,

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-14
• Study Completion: 2020-10-30
• Last Update Posted: 13 November 2023

Recruitment & Eligibility

• Status: Suspended
• Sex: Not specified
• Target Recruitment: 42

Inclusion Criteria

A.Healthcare workers in service during the COVID-19 outbreak including medical, nurse, technical and auxiliary staff.
B.Negative rapid serologic and molecular testing for SARS-CoV-2.
C.Written informed consent.

Exclusion Criteria

A.Presents COVID-19 symptoms including cough, fever, myalgias, headaches, loss of smell and taste
B.Prior (last 30 days) or current (or planned use during the study period) use of hydroxychloroquine, chloroquine sulfate or azithromycin.
C.Known history of prolonged QT syndrome.
D.Known allergy or intolerance to hydroxychloroquine.
E.Use of concomitant medications that are contraindicated with the use of hydroxychloroquine.
F.Participation might not be beneficial, by investigator judgement.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br>Outcome name:Positive confirmatory or serologic testing for SARS-CoV-2<br>Measure:Efficacy<br>Timepoints:4 and 8 weeks<br>;<br>Outcome name:Proportion of patients with grade 3 or more adverse events<br>Measure:Safety<br>Timepoints:4 and 8 weeks<br>

Secondary Outcome Measures

Name	Time	Method
<br>Outcome name:Proportion of participants that discontinue prophylactic treatment due to grade 1 o 2 adverse events<br>Measure:Tolerability<br>Timepoints:4 and 8 weeks<br>